MedTrace Logo

Epidemiologic Study Of Diabetes And Cancer Risk

NCT02958995 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2738161

Last updated 2018-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes along with the assessment of association between diabetes severity and cancer risk.

Conditions

  • Diabetes Mellitus, Type 2, Cancer

Interventions

OTHER

No Intervention

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-01-01
Primary Completion
2015-05-29
Completion
2015-05-29

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958995 on ClinicalTrials.gov